{"name":"Subhransu K. Ray, M.D., Ph.D.","slug":"subhransu-k-ray-m-d-ph-d","ticker":"","exchange":"","domain":"","description":"Subhransu K. Ray, M.D., Ph.D. is a biopharmaceutical company focused on the development of novel therapies for ophthalmic conditions. The company's lead product is in Phase 1 clinical trials, targeting a significant unmet medical need.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ranibizumab and dexamethasone","genericName":"ranibizumab and dexamethasone","slug":"ranibizumab-and-dexamethasone","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ranibizumab and dexamethasone","genericName":"ranibizumab and dexamethasone","slug":"ranibizumab-and-dexamethasone","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}